Oasis Outsourcing Helps Businesses Navigate Through Adjusted Community Rating

West Palm Beach, FL Jul 31, 2014 – Oasis Outsourcing, one of the nation’s leading Professional Employer Organizations (PEOs), has released a new infographic designed to help businesses, understand how the Adjusted Community Rating provision of the Affordable Care Act (ACA) works. Adjusted Community Rating is a way of pricing insurance where premiums are not based on a policy holder’s health status, but may be based on other factors such as age and geographic location. Additionally, carriers are required to consider individuals and small groups as one community or risk pool.
Since Adjusted Community Rating went into effect in January 2014, there has been a big change in how small group insurance is calculated. The infographic created by Oasis Outsourcing easily explains the changes and helps small businesses choose the best course of action. Since carriers can only use a limited set of factors when setting rates, some groups that historically would have received favorable ratings, for example younger populated groups, might see significant increases while others that historically would have been assigned very expensive rates, may see rates decrease.
Oasis Outsourcing has expertise in all areas of Healthcare Reform legislation and can help any business navigate through the various provisions regardless of plan type.
The new infographic is available for use at www.oasisadvantage.com/aca-infographic.

Oasis Outsourcing Ranked Third in This Year’s South Florida Business Journal’s Top 100 Private Companies

West Palm Beach, FL Jul 21, 2014 – Oasis Outsourcing jumped two spots and ranked third on the South Florida Business Journal’s (SFBJ) 2014 Top 100 Private Companies list. In its 11th year, the Top 100 Private Company compilation based its rankings on each company’s revenue from the previous year. Additionally, Oasis Outsourcing’s $300 million increase in revenue from 2012 to 2013 ranked fifth on the SFBJ’s Top 10 Biggest Dollar Growth list.
“We are honored to be recognized among South Florida’s best-in-class companies,” said Mark Perlberg, President and CEO of Oasis Outsourcing. “We are extremely pleased with the success we had in the past year and are proud of our company’s growth in Florida and across the nation.”

HealthTronics Announces Distribution Agreement with HS Medical

HealthTronics Expands Minimally Invasive, Cancer Technology Portfolio
Now independent, company seeks new partners as part of strategic growth
Austin, TX Jul 8, 2014 — HealthTronics, Inc., a leading provider of integrated urological and interventional radiology products and services, has signed a distribution agreement through its Endocare, Inc. subsidiary with HS Medical, Inc. that expands HealthTronics’ technology portfolio to include a new, targeted ablation solution.
Under the agreement, HealthTronics will make available HS Medical’s new generation of HS Amica® microwave ablation apparatus to health care providers and their patients. (www.hsmedicalinc.com)
Microwave ablation is a targeted, minimally invasive procedure that uses a “heating probe” to ablate soft tissue. The procedure works by applying heat directly into the tissue through the probe, which agitates water molecules in the tissue, generates heat, and causes ablation of the tissue. The HS Amica® system is FDA-cleared for thermal ablation of soft tissue other than cardiac tissue and is typically used for ablation of liver, lung and kidney tissue. Its exclusive “mini-choke” technology provides optimum control of the microwave field within the ablation target.
“Microwave ablation complements our technology portfolio of minimally invasive, targeted approaches to treating tissue,” said Russell Newman, President of HealthTronics. “The agreement also underscores our commitment to bring to doctors and patients products that meet their needs—namely, minimally invasive, economical and effective.”
Newman says that since becoming an independent company following the divestiture from Endo International plc in February 2014, HealthTronics has been actively looking to expand its portfolio of products and services, including seeking FDA clearance for additional therapeutic applications of its existing cryotherapy technology.
The technologies currently offered by the company include Endocare® cryotherapy systems for ablation of prostate, kidney and lung cancer tumors, lithotripters for dissolving kidney stones, lasers for treating benign prostate hyperplasia (BPH) and nerve monitoring equipment for use during robotic prostate surgery.

Thoma Bravo to Acquire Sparta Systems

Thoma Bravo investment in Sparta Systems signals growth opportunities for EQMS leader
San Francisco, CA Jul 7, 2014 – Thoma Bravo, LLC, a leading private equity investment firm, announced that it has entered into an agreement to acquire Sparta Systems, Inc., a global leader in enterprise quality management solutions (EQMS), from current investors Summit Partners and Altaris Capital Partners. Financial details were not disclosed, and the transaction is expected to close in the third quarter of 2014.
“We are excited about the Sparta Systems acquisition due to the compelling opportunities for growth, both organically and from additional acquisitions that enhance the company’s offerings,” said Scott Crabill, a managing partner at Thoma Bravo. “As a proven EQMS leader with a strong customer base and a defensible position in the industry, it fits our investment and company growth strategy extremely well.”
Founded in 1994, Sparta Systems currently has over 650,000 users in more than 30 countries. The company maintains an extensive customer base in many highly regulated industries, which includes the top 30 pharmaceutical, 12 of the top 15 medical device and leading consumer products and discrete manufacturing companies.
The company offers a platform – led by its flagship product TrackWise® – that enables manufacturers to deliver products to market safely and efficiently. Sparta’s solutions provide powerful visibility and traceability across its customers’ quality management activities, allowing organizations to address a multitude of escalating challenges including: mounting regulatory oversight, increased public scrutiny, growing supply chain and business process complexity and increased pressure to deliver greater profits. In addition, the company recently released Stratas™, a revolutionary, cloud-based solution that extends TrackWise beyond a corporation’s four walls to external suppliers and manufacturers.
“Thoma Bravo’s investment allows us to continue our superior growth trajectory, by strengthening our ability to deliver innovative solutions to customers faster, as well as accelerate our vertical market growth,” said Eileen Martinson, CEO of Sparta Systems. “I’m confident that this will enable us to not only enhance our current customer offerings, but to be opportunistic about acquisitions that will add to our product portfolio.”
“Eileen along with her management team have built an incredible company, and we couldn’t have been more impressed with the people at Sparta Systems,” said Arvindh Kumar, vice president at Thoma Bravo. “We look forward to partnering with them to continue building on their position as the preeminent EQMS provider.”
Kirkland & Ellis LLP served as legal advisor to Thoma Bravo. Lazard acted as financial advisor and Proskauer as legal advisor to Sparta Systems.

AMRI Completes Acquisition of OSO Biopharmaceuticals Manufacturing

Albany, NY Jul 1, 2014 – AMRI (NASDAQ: AMRI) today announced that it has completed the acquisition of Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris Capital Partners, LLC. The transaction is consistent with AMRI’s strategy to be the preeminent supplier of custom and complex drug product development and manufacturing services to the pharmaceutical industry.
OsoBio is recognized as a premier contract manufacturer of highly complex injectable drug products and their expertise in large-scale commercial production is highly complementary to AMRI’s early stage drug product manufacturing capabilities. Customers will benefit from access to a single source to address their sterile fill/finish needs from Phase 1 development complete to commercial supply.
Total consideration paid was $110 million. AMRI financed the transaction with cash on hand. AMRI anticipates full year run-rate synergies of approximately $3.0 million of EBITDA within 12 months of closing and the acquisition is expected to be accretive to AMRI’s 2014 adjusted diluted EPS. AMRI intends to provide investors with updated 2014 guidance for the combined company when it releases its second quarter 2014 financial results on August 5, 2014.